A complete application in a minute — tailored resume and cover letter, ready to send.
Kelly Science & Clinical is seeking a Vice President of Preclinical and Clinical Development for a leading nonprofit translational research institute in San Diego, CA. This on‑site role drives strategy and execution across preclinical and early clinical programs, bringing IND‑enabling packages from discovery to first‑in‑human trials.
You will lead in vivo pharmacology, efficacy, toxicology, ADME/PK, and collaborate across chemistry, biology, regulatory, and clinical teams, ensuring GLP/GMP
Kelly® Science & Clinical is seeking a Vice President of Preclinical and Clinical Development opportunity with one of our clients, a leading non‑profit translational research institute in San Diego, CA. If you are driven by the prospect of translating cutting‑edge scientific discoveries into tangible advancements and are poised to advance your career, join us as we pioneer progress in the biotechnology industry.
Position Title: Vice President, Preclinical and Clinical Development
Salary range: 300,000-320,000/year
Are you ready to shape the future of medicine at the intersection of world‑class biomedical science and breakthrough innovation? Join a cutting‑edge nonprofit translational research institute driven to accelerate new drug development and transform patient outcomes, spanning a diverse range of human diseases.
We seek an accomplished and visionary Vice President of Preclinical & Clinical Development to drive strategy and execution across the full continuum of preclinical drug development. This senior, on‑site executive will provide scientific and operational leadership for in vivo pharmacology, efficacy, toxicology, and ADME/PK, bringing early‑stage therapeutic candidates from discovery through IND filing and into early clinical trials.
This is a rare opportunity to lead talented, cross‑functional teams in both small molecule and biologics programs, with responsibility for guiding foundational research, developing robust IND‑enabling packages, and shaping drug development strategy for a dynamic, high‑impact portfolio.